Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) news covers developments at a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches and nanotechnology platforms. As a dual-listed issuer on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix regularly publishes updates that are relevant to investors following oncology-focused biotechnology and pharmaceutical preparation manufacturing.
Company news frequently highlights progress in the JNJ-1900 (NBTXR3) clinical program, including updates on the global Phase 3 NANORAY-312 study in locally advanced head and neck squamous cell cancers and Phase 1 and Phase 2 studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Releases may also describe regulatory designations, collaboration milestones with Janssen Pharmaceutica NV, and the transfer of sponsorship and operational control of key trials.
Another recurring theme in Nanobiotix news is the Curadigm Nanoprimer platform. The company reports on new patent applications, preclinical in vivo data, and Chemistry, Manufacturing, and Controls (CMC) activities, as well as material transfer agreements with biotechnology and pharmaceutical partners evaluating Nanoprimer combinations with intravenously administered therapeutics.
Investors can also find announcements related to capital markets activity, such as royalty-based financing agreements with HealthCare Royalty (HCRx), inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, and periodic disclosures on shares outstanding and voting rights under French regulations. In addition, Nanobiotix issues notices about participation in investor and healthcare conferences, where management presents the company’s strategy and clinical pipeline.
By following NBTX news, readers can track clinical, financial, and strategic updates that shape the company’s development trajectory and its work in oncology, drug bioavailability and biodistribution, and central nervous system disorder applications.
Nanobiotix (NASDAQ: NBTX) has reported its latest voting rights and share capital status as of July 31, 2025. The company disclosed a total of 48,236,671 shares outstanding, with 50,340,736 theoretical voting rights and 50,318,618 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, with dual listings on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix (NASDAQ: NBTX) announced two significant developments for its radioenhancer JNJ-1900 (NBTXR3). First, major European health authorities have reclassified the product from a medical device to a medicinal product, aligning with its status in the US and other major markets. This reclassification follows updated insights into the product's mechanism of action.
Second, the company has filed a new composition of matter patent for JNJ-1900, which is currently licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company. The product is undergoing extensive global clinical development, including a pivotal Phase 3 trial in head and neck cancer, across multiple tumor types and therapeutic combinations.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on June 5, 2025, at 3:45 PM EDT in New York. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.
Nanobiotix (NBTX) reported key operational and financial updates for Q1 2025. The company achieved significant milestones in its JNJ-1900 (NBTXR3) development programs, including the dosing of the first patient in the CONVERGE Phase 2 study for stage 3 unresectable non-small cell lung cancer. Clinical data presentations at major conferences demonstrated promising results in lung cancer re-irradiation and pancreatic cancer studies.
The company strengthened its financial position through an amendment to the global licensing agreement for JNJ-1900, which extended its cash runway into mid-2026 and reduced operational cash burn. As of March 31, 2025, Nanobiotix reported €39.8 million in cash and cash equivalents. The agreement modification removed most funding obligations for NANORAY-312 while maintaining potential milestone and royalty payments.
Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of April 30, 2025. The company disclosed having 47,426,851 shares outstanding, with 49,535,883 theoretical voting rights and 49,513,765 exercisable voting rights. This regular monthly disclosure is required by French regulatory authorities for companies listed on Euronext Paris.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on Tuesday, May 20, 2025, at 5:00 pm EDT in New York. The presentation will be webcast live and available for replay on the company's investor relations website.
Nanobiotix (NBTX) announced full results from a completed Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer patients. The study, conducted at MD Anderson Cancer Center, showed promising outcomes in patients with locally advanced or borderline resectable pancreatic cancer (n=22). Key findings include:
- Median Overall Survival of 23 months from diagnosis [compared to 19.2 months historical data] - Median Local Progression-Free Survival of 13.3 months from radiation completion - CA19-9 normalization in 59% of patients (vs 17% historical data) - Two LAPC patients achieved R0 surgical resection - Favorable safety profile and injection feasibility
The study has expanded with a new cohort combining JNJ-1900 with standard-of-care concurrent chemoradiation after induction chemotherapy, with the first patient already injected.
Nanobiotix has announced the upcoming presentation of complete results from their Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer patients. The presentation will take place at ESTRO 2025 on May 4th at 11:00 AM EDT, delivered by Principal Investigator Dr. Eugene Koay.
The study focused on patients with locally advanced or borderline resectable pancreatic cancer, conducted at The University of Texas MD Anderson Cancer Center. Following the presentation, Nanobiotix will host a conference call on May 5th at 8:00 AM EDT, featuring CEO Laurent Levy to discuss the findings.
The company, listed on both Euronext (NANO) and NASDAQ (NBTX), is advancing their nanoparticle-based therapeutic approach to expand cancer treatment options. Participants can join the discussion through either a webcast or audio-only option, with the opportunity to submit questions in advance to investors@nanobiotix.com.
Nanobiotix (NBTX) has released its latest voting rights and share capital statement as of March 31, 2025. The company reported 47,426,851 shares outstanding, with 49,193,374 theoretical voting rights and 49,171,256 exercisable voting rights. This disclosure complies with French regulatory requirements, including the French Commercial Code and Financial Markets Authority regulations.